SOLICITATION NOTICE
Q -- Intent to Sole Source to Inova Health System, Inova Fairfax Hospital, Falls Church, VA
- Notice Date
- 2/12/2013
- Notice Type
- Presolicitation
- NAICS
- 622310
— Specialty (except Psychiatric and Substance Abuse) Hospitals
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-CSB-HL-2013-79-RRJ
- Archive Date
- 2/27/2013
- Point of Contact
- Robin Jeffries, Phone: 3014350376
- E-Mail Address
-
robin.jeffries@nih.gov
(robin.jeffries@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a Pre-Solicitation/Notice of Intent Synopsis for a sole source noncompetitive award to Inova Health System, Inova Fairfax Hospital, Falls Church, VA for the NIH-Inova Pulmonary Vascular Program: Dedicated to the Reversal of Pulmonary Hypertension and Advanced Lung Disease. The National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), Office of Acquisitions (OA), on behalf of the NHLBI/DIR Cardiovascular-Pulmonary Branch intends to negotiate and award a contract on a sole source noncompetitive basis for the NIH-Inova Pulmonary Vascular Program: Dedicated to the Reversal of Pulmonary Hypertension and Advanced Lung Disease to Inova Health System, Inova Fairfax Hospital, Falls Church, VA. The National Institutes of Health (NIH) specifically the Vascular Medicine Branch of the National Heart Lung and Blood Institute (NHLBI) required the development of an Advanced Lung Disease Program (referred to as "Program") dedicated to the management and study of patients with the various forms of pulmonary arterial hypertension (PAH). The National Heart, Lung, and Blood Institute (NHLBI)at the National Institute of Health (NIH) contracted with Inova Health System, Inova Fairfax Hospital to establish a collaborative Pulmonary Arterial Hypertension (PAH) program. The program utilizes Inova's current facilities and the Heart Institute's clinical practice and research abilities. NIH has a long history of an established integrative clinical research approach. Its Pulmonary Vascular team in the Vascular Medicine Branch of the Heart Institute consists of physicians with expertise in pulmonary, hematology and cardiovascular diseases, all critical components in the management of pulmonary arterial hypertension patients. Inova-Fairfax Hospital has a well established Pulmonary Hypertension Program with clinicians and coordinators skilled in the management and care of patients with various forms of pulmonary vascular disease. The program combines the NIH and Inova Pulmonary Vascular Program has provided substantial benefits for both institutes and the affected patient population. All patients recruited through NIH for study purposes would have the option of being followed/managed clinically through the Program. Inova would provide the day-to-day clinical management and care with the collaborative assistance of NHLBI. This is a follow-on contract of the previous Inova Health System contract (Contract No. HHSN268200700032C) which established the program for the management and study of patients with various forms of pulmonary disease. Inova is the only contractor that can perform this work since they have established the program and need to perform the research studies. In support of the Program, Inova is in the development of an ongoing NHLBI asthma treatment clinical trial, as well as on three additional NHLBI clinical protocols. The Inova Fairfax Advanced Lung Disease Program will actively recruit patients with pulmonary diseases, such as asthma, sarcoidosis, and lymphangioleiomyomatosis, to NHLBI clinical protocols. This will include inclusion of NHLBI clinical protocols in mailed announcements by the INOVA Fairfax Advanced Lung Disease Program. Inova Fairfax Advanced Lung Disease Program physicians will provide clinical coverage and management of pulmonary hypertension and other advanced lung disease patients in the Monday NHLBI Pulmonary Hypertension Clinic. Inova Fairfax Advanced Lung Disease Program physicians will provide clinical guidance regarding the management of NIH pulmonary hypertension patients, as well as other advanced lung diseases, in both in-patient and out-patient settings. NIH will have access to all patients evaluated at Inova for possible patient enrollment in NHLBI clinical trials and care of Inova patients in NIH clinical trials. The period of performance will be April 1, 2013 through March 31, 2018 ((1) one-year base period with four (4) one-year options). The basis for the sole source determination is based upon the fact that: Inova Health System, Inova Fairfax Hospital, Falls Church, VA is the sole source for the follow-on contract for the continuation of the NIH-Inova Pulmonary Vascular Program: Dedicated to the Reversal of Pulmonary Hypertension and Advanced Lung Disease. Inova has a well-established Advanced Lung Disease and Pulmonary Hypertension Program with clinicians and coordinators skilled in the management and care of patients with various forms of pulmonary disease. Inova is the only contractor that can perform this work since they have established the program and need to perform the research studies. Inova actively participates in the evaluation, management and enrollment of severe asthmatic patients into NHLBI clinical research protocols. Inova has an important role in the recruitment of severe asthmatic patients to NHLBI research studies. Inova serves as NIH's primary conduit for patient recruitment and referral from the Northern Virginia medical community and has facilitated the recruitment of severe asthmatic patients on several levels. Thus, the contract/program has been very important for the recruitment and referral of severe asthmatic patients to NIH research studies. Further Inova has referred patients with lymphangioleiomyomatosis (LAM) and congenital heart disease to NHLBI. Lastly, the INOVA Fairfax Advanced Lung Disease Program has also supported other NIH clinical research protocols and has referred over 443 patients for participation. This acquisition is conditioned under the authority of 41 U.S.C. 253 (c) as set forth in FAR Part 6.302-1 (b), Only one responsible source and no other supplies or services will satisfy agency requirements. The North American Classification System (NAICS) code applicable to this requirement is 622310 - Speciality (except Psychiatric and Substance Abuse) Hospitals with a size standard of $35.5 million. This Pre-Solicitation/Notice of Intent is not a request for competitive proposals. This announcement constitutes the only notice; proposals are not being request and a written solicitation will not be issued. The determination by the Government to award a contract on a sole source noncompetitive basis for the NIH-Inova Pulmonary Vascular Program: Dedicated to the Reversal of Pulmonary Hypertension and Advanced Lung Disease to Inova Health System, Inova Fairfax Hospital, Falls Church, VA is solely within the discretion of the Government. Any information received as a result of this Pre-Solicitation/Notice of Intent will be considered solely for the purpose of determining whether to conduct any future competitive procurement. Interested parties may identify their interest and capability for any future competitive procurement by responding to this notice in writing, no later than February 26, 2013 at 11:59 p.m. EST. Responses to this notice shall contain sufficient documentation to establish the interested parties' bona-fide capabilities for fulfilling the requirement. All responses must reference this Pre-Solicitation/Notice of Intent number NHLBI-CSB-HL-2013-79-RRJ and may be submitted electronically to Robin Jeffries, Contracting Officer at robin.jeffries@nih.gov or by mail to the National Heart, Lung, and Blood Institute, Office of Acquisitions, 6701 Rockledge Drive, Suite 6122, Bethesda, MD 20892-7902, Attention: Robin Jeffries, Contracting Officer.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-CSB-HL-2013-79-RRJ/listing.html)
- Place of Performance
- Address: 6701 Rockledge Drive, Room 6122, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02985369-W 20130214/130212234258-36e9fce7be1c862dc7f5d148cabfb4b5 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |